Director Shareholding

GlaxoSmithKline PLC
21 January 2005


                              Director's Interests

I give below details of changes in directors' interests in the Ordinary Shares
of GlaxoSmithKline plc.


17 December 2004         The Administrators of the Trust notified the Company 
                         on 20 January 2005 that 973 Ordinary shares in the 
                         Company had been sold on 17 December 2004 on behalf of 
                         a participant in the SmithKline Beecham Bonus 
                         Investment Plan at a price of £11.69.

                         The Trust also notified the Company on 20 January 2005 
                         that 1,389 Ordinary shares had been transferred from 
                         the Trust to a participant in the SmithKline Beecham 
                         Bonus Investment Plan.


13 January 2005          The Administrators of the Trust notified the Company on 
                         20 January 2005 that following reinvestment of the cash 
                         dividend paid to shareholders on 06 January 2005, 1,127 
                         Ordinary Shares in the Company had been purchased for 
                         participants in the SmithKline Beecham Bonus Investment 
                         Plan at a price of £12.43

                         The Administrators of the SmithKline Beecham Employee 
                         Benefit Trust ("the Trust") notified the Company on 20 
                         January 2005 that 929 Ordinary shares had been 
                         transferred from the Trust to participants in the 
                         SmithKline Beecham Unapproved Share Match Plan.

17 January 2005          The Administrators of the Trust notified the Company on 
                         20 January 2005 that following reinvestment of the cash 
                         dividend paid to shareholders on 06 January 2005, 7,560 
                         Ordinary Shares in the Company had been purchased for 
                         participants in the GlaxoSmithKline Annual Investment 
                         Plan at a price of £12.15


The Trust is a discretionary fund of which all non US employees or former
employees of GlaxoSmithKline plc and its subsidiaries are potential
beneficiaries. One of the Company's directors, John Coombe is therefore
interested in the shares held in the fund from time to time in the same way as
other non US employees or former employees of GlaxoSmithKline plc and its
subsidiaries.

S M Bicknell
Company Secretary

21 January 20050


                      This information is provided by RNS
            The company news service from the London Stock Exchange